This HTML5 document contains 82 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n14http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00240/identifier/kegg-drug/
n8http://linked.opendata.cz/resource/drugbank/company/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00240/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/dosage/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00240/identifier/national-drug-code-directory/
n15http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00240/identifier/chebi/
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n21http://www.drugs.com/cdi/
n5http://linked.opendata.cz/resource/drugbank/property/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00240/identifier/wikipedia/
n24http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00240/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00240
rdf:type
n3:Drug
n3:description
Alclometasone is synthetic glucocorticoid steroid for topical use in dermatology as anti-inflammatory, antipruritic, antiallergic, antiproliferative and vasoconstrictive agent. [Wikipedia]
n3:dosage
n4:271B633E-363D-11E5-9242-09173F13E4C5 n4:271B633F-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
n3:manufacturer
n8:271B632D-363D-11E5-9242-09173F13E4C5 n8:271B6330-363D-11E5-9242-09173F13E4C5 n8:271B6331-363D-11E5-9242-09173F13E4C5 n8:271B632E-363D-11E5-9242-09173F13E4C5 n8:271B632F-363D-11E5-9242-09173F13E4C5
owl:sameAs
n10:DB00240 n15:DB00240
dcterms:title
Alclometasone
adms:identifier
n17:53776 n18:68462-300-17 n19:DB00240 n20:D01820 n22:PA164747650 n23:Alclometasone
n3:mechanismOfAction
The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A<sub>2</sub> inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A<sub>2</sub>. Alclometasone initially binds the corticosteroid receptor. This complex migrates to the nucleus where it binds to different glucocorticoid response elements on the DNA. This in turn enhances and represses various genes, especially those involved in inflammatory pathways.
n3:packager
n8:271B632C-363D-11E5-9242-09173F13E4C5 n8:271B632A-363D-11E5-9242-09173F13E4C5 n8:271B632B-363D-11E5-9242-09173F13E4C5 n8:271B6328-363D-11E5-9242-09173F13E4C5 n8:271B6329-363D-11E5-9242-09173F13E4C5 n8:271B6326-363D-11E5-9242-09173F13E4C5 n8:271B6327-363D-11E5-9242-09173F13E4C5
n3:synonym
Aclometasone 7alpha-Chloro-16alpha-methylprednisolone 7α-Chloro-16α-methylprednisolone
n3:toxicity
Symptoms of overdose include suppression of adrenal glands, temporary decrease in white blood cell counts, symptoms of hypersensitivity (such as skin rash, hives, itching, and difficulty breathing), and increased susceptibility to infection.
n3:salt
foaf:page
n14:alclometasone.htm n21:alclometasone-cream.html n24:acl1005.shtml
n3:IUPAC-Name
n5:271B6344-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B634A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B6349-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B6346-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B6347-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B6348-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B635A-363D-11E5-9242-09173F13E4C5 n5:271B6342-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B635B-363D-11E5-9242-09173F13E4C5 n5:271B6340-363D-11E5-9242-09173F13E4C5 n5:271B6343-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B6341-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n7:S01BA10 n7:D07AB10
n3:H-Bond-Acceptor-Count
n5:271B6350-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B6351-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B634B-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B634C-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B634E-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B634D-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B634F-363D-11E5-9242-09173F13E4C5
n3:absorption
Topical corticosteroids can be absorbed from normal intact skin. Studies have shown that approximately 3% of steroid is absorbed during 8 hours of contact with intact skin of normal volunteers.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
66734-13-2
n3:category
n3:containedIn
n12:271B6336-363D-11E5-9242-09173F13E4C5 n12:271B6337-363D-11E5-9242-09173F13E4C5 n12:271B6334-363D-11E5-9242-09173F13E4C5 n12:271B6335-363D-11E5-9242-09173F13E4C5 n12:271B6332-363D-11E5-9242-09173F13E4C5 n12:271B6333-363D-11E5-9242-09173F13E4C5 n12:271B633C-363D-11E5-9242-09173F13E4C5 n12:271B633D-363D-11E5-9242-09173F13E4C5 n12:271B633A-363D-11E5-9242-09173F13E4C5 n12:271B633B-363D-11E5-9242-09173F13E4C5 n12:271B6338-363D-11E5-9242-09173F13E4C5 n12:271B6339-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B6356-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B6358-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B6359-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B6355-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B6354-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B6357-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B6345-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B6352-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B6353-363D-11E5-9242-09173F13E4C5